Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Y-QOL study: Sodium Zirconium Cyclosilicate for hyperkalemia in hemodialysis patients
jRCTs031230404Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised trial of sodium zirconium cyclosilicate in chronic kidney disease (CKD), end-stage kidney disease (ESKD) and hyperkalemia (2 arms), sponsored by AstraZeneca. Primary endpoint: Change in QDIS-7 score at Week 8 from baseline. Started Jan 2024; status: completed.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
chronic kidney disease (CKD)end-stage kidney disease (ESKD)hyperkalemia
Beyond the preview
Go deeper on jRCTs031230404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230404.